Allarity presents novel DRP for daratumumab in multiple myeloma at AACR

Allarity Therapeutics, Inc.

First DRP developed for an antibody therapy (daratumumab), expanding platform beyond small molecules.
DRP identified 53 genes (27 sensitivity, 26 resistance) from in vitro data and KYDAR trial bone marrow samples.
Predictor aims to identify multiple myeloma patients likely to benefit from daratumumab; presented at AACR 2025.
Management highlights potential for future collaborations to bring precision diagnostics to more patients.
Allarity's lead program, stenoparib (dual PARP/WNT inhibitor), remains in Phase 2 for ovarian cancer and small cell lung cancer.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.